Navigation Links
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Date:4/7/2008

Clinical proof of concept achieved with proprietary drug combination

technology

MOUNTAIN VIEW, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), today announced positive results from a Phase 2a clinical study evaluating MAP0005 for the potential treatment of asthma and chronic obstructive pulmonary disease (COPD). MAP0005 is a single-particle combination of budesonide, a corticosteroid, and formoterol, a long-acting beta2-agonist, delivered to the respiratory tract using the Company's proprietary Tempo(R) inhaler.

"The results of our Phase 2a trial with MAP0005 demonstrate our ability to apply our proprietary technologies to combine two drugs within a single particle in a pre-specified ratio and deliver them to the lung," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "We believe this approach has the potential to address formulation and stability constraints often seen in the development and production of inhaled combination products. Our goal is to improve safety and efficacy by targeting consistent dose ratios and reducing systemic exposure to the beta-agonist. This approach has potential broad applicability for additional combination product candidates in a variety of indications."

This randomized, open-label, active-controlled, crossover, safety and dose response study investigated the pharmacokinetics (PK) and pharmacodynamics of MAP0005 in 15 adult asthmatics. The trial assessed the ability of MAP0005 to deliver budesonide to the lungs, as measured by PK, and formoterol to conducting airways in amounts sufficient to provide bronchodilation, both compared to the leading currently approved budesonide/
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned ... market share and grab a foothold in the hydroponic, hemp ... capabilities and a presence in the sector, and recently partnering ... growth of hemp and medical marijuana, iMD is committing to ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Jan. 26, 2012 Masimo (NASDAQ: MASI ... year financial results for the period ended December 31, 2011, after ... review the results will begin at 1:30 p.m. PT (4:30 p.m. ... Executive Officer, and Mark P. de Raad, Executive Vice President and ...
... Dr. Ira J. Haimowitz, Executive Vice President, Group Director, Intelligence ... at the eMarketing University for Brand Managers, a symposium at ... 2012. The symposium is a full-day course designed ... tactics into their marketing mix. Dr. Haimowitz will be presenting ...
Cached Medicine Technology:Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012 2Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012 3Ira Haimowitz, PhD, EVP, at The CementBloc, to Present on Best Practices in iPad Interactive Selling at 11th Annual ePharma Summit™ 2
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
(Date:1/22/2015)... Mass. (PRWEB) January 22, 2015 EBSCO ... (AMA) are expanding their relationship in an effort to ... around the world. While EBSCO has long made AMA journals ... a sales agent for The JAMA Network. , ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... LANSING, Mich., March 27 Accident Fund Insurance,Company ... its,outstanding achievements in creating a safe work environment. ... experiencing one lost-time,incident, when in 2006 the Michigan ... employees unable to work. Clark Construction,received the Gold ...
... Support Health Plans Next Generation of Care Management ... and Special Need Populations, SAN ANTONIO and AUBURN, ... only locally owned and operated,non-profit HMO, announced today that ... to support its next,generation of care management programs sponsored ...
... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the,Campaign for Tobacco-Free Kids. Hundreds of ... local events, go to http://www.kickbuttsday.org/events )., This ...
... Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... tobacco on April 2 as they join thousands of ... sponsored by the,Campaign for Tobacco-Free Kids. Hundreds of events ... events, go to, http://www.kickbuttsday.org/events )., This year, Kick ...
... Proposed Bush FY 2009 Budget Slashes Nursing Home ... Medicare Cuts Place Greater,Pressure on State Medicaid Program ... National and state,front line caregivers voiced opposition ... care for Michigan seniors contained in the,Bush Administration,s ...
... properties of bitter melon, a vegetable and traditional Chinese ... 2 diabetes. , Teams from the Garvan Institute of ... pulped roughly a tonne of fresh bitter melon and ... all appear to activate the enzyme AMPK, a protein ...
Cached Medicine News:Health News:Accident Fund Recognizes Clark Construction Co. for 2 Million Hours without a Lost-Time Injury 2Health News:Community First Health Plans Selects TCS Healthcare Technologies' Care Management Software System 2Health News:Community First Health Plans Selects TCS Healthcare Technologies' Care Management Software System 3Health News:California Kids 'Kick Butts' on April 2 2Health News:California Kids 'Kick Butts' on April 2 3Health News:Georgia Kids 'Kick Butts' on April 2 2Health News:Georgia Kids 'Kick Butts' on April 2 3Health News:National, State Front Line Caregivers Warn About $64 Million Cut to Medicare Funding for Care of Michigan Seniors 2Health News:National, State Front Line Caregivers Warn About $64 Million Cut to Medicare Funding for Care of Michigan Seniors 3Health News:National, State Front Line Caregivers Warn About $64 Million Cut to Medicare Funding for Care of Michigan Seniors 4Health News:A ton of bitter melon produces sweet results for diabetes 2
... the 17 million echocardiograms performed annually ... DEFINITY increases the power of echocardiography, ... than with echo alone. As a ... for many patientsby illuminating the heart, ...
... Launched in 1996, VISIPAQUE is the only ... With an osmolality equal to that of blood, ... VISIPAQUE is also the only contrast medium formulated ... to blood. In 1997, VISIPAQUE received FDA approval ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
... Padgett's commitment to quality and innovation has ... product developments: The Model C is an ... required for instruments in burn care surgery. ... constructed with the same dedication to quality, ...
Medicine Products: